Back to Search
Start Over
Anti-cytotoxic T lymphocyte antigen-4 (CTLA-4) immunotherapy for the treatment of prostate cancer
- Source :
-
Urologic Oncology . Sep2006, Vol. 24 Issue 5, p442-447. 6p. - Publication Year :
- 2006
-
Abstract
- Abstract: Costimulatory pathway ligands and receptors can deliver either positive or negative signals to help determine the ultimate fate of activated T lymphocytes. Cytotoxic T lymphocyte antigen-4 (CTLA-4) represents one of the most extensively studied receptors in the costimulatory pathway and has recently been shown to function as a potent inhibitor of T cell-mediated immunity. T-cell expression of CTLA-4 indirectly facilitates tumor progression by restraining host antitumoral immunity. In contrast, administration of a monoclonal antibody to block CTLA-4 function can alleviate restraints on T-cell activity to promote immune-mediated tumor regression. We review the preclinical and clinical experience with CTLA-4 blockade as a promising immunotherapeutic approach to treat patients with advanced prostate cancer. [Copyright &y& Elsevier]
- Subjects :
- *LYMPHOCYTES
*IMMUNOTHERAPY
*ANTIGENS
*PROSTATE cancer
Subjects
Details
- Language :
- English
- ISSN :
- 10781439
- Volume :
- 24
- Issue :
- 5
- Database :
- Academic Search Index
- Journal :
- Urologic Oncology
- Publication Type :
- Academic Journal
- Accession number :
- 22281699
- Full Text :
- https://doi.org/10.1016/j.urolonc.2005.08.011